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Abstract
Background: Liraglutide 3 mg was recently approved as an anti-obesity drug. Metformin is weight neutral, yet it
could enhance the therapeutic index of GLP-1 agonist. We compared weight-lowering potential of liraglutide 1.
2 mg in combination with metformin to liraglutide 3 mg monotherapy in obese PCOS.
Methods: Thirty obese women with PCOS (aged 33.1 ± 6.1 years, BMI 38.3 ± 5.4 kg/m2) were randomized to
combination (COMBO) of metformin (MET) 1000 mg BID and liraglutide 1.2 mg QD (N = 15) or liraglutide 3 mg
(LIRA3) QD alone (N = 15) for 12 weeks. The primary outcome was change in anthropometric measures of obesity.
Results: Both treatments led to significant weight loss (−3.6 ± 2.5 kg, p = 0.002 in COMBO vs −6.3 ± 3.7 kg, p = 0.001
in LIRA3). BMI and waist circumference reduction in LIRA3 was greater than in COMBO (−2.2 ± 1.3 vs −1.3 ± 0.9 kg/
m2, p = 0.05 and −4.2 ± 3.4 vs −2.2 ± 6.2 cm, p = 0.014, respectively). Both interventions resulted in a significant
decrease of post-OGTT glucose levels. COMBO significantly reduced total testosterone and was associated with less
nausea.
Conclusions: Short-term interventions with COMBO and LIRA3 both led to significant improvement of measures of
obesity in obese PCOS, LIRA3 being superior to COMBO. However, COMBO further improved androgen profile
beyond weight reduction and was associated with better tolerability.
Trial registration: The study was retrospectively registered with ClinicalTrials.gov (NCT02909933) on 16th of
September 2016.
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Background
Obesity is present in 50–80% of women with polycystic
ovary syndrome (PCOS) [1]. Even a modest weight loss
of 5–10% is primarily important for reduction of cardio-
vascular risk factors and improvement of fertility poten-
tial [2–4]. First line recommended lifestyle therapy for
weight management often remains unsatisfactory and
non-sustainable in clinical practice [5–7].
Liraglutide, a long acting glucagon-like peptide-1
(GLP-1) analogue, has a dose dependent dual beneficial
effect. It improves glucose homoeostasis and reduces
body weight. As anti-diabetic therapy is approved at
doses up to 1.8 mg [8], whereas higher doses are re-
quired for maximum weight reduction [9, 10]. Liraglu-
tide 3 mg led to decreases in body weight of more than
5 to as much as 15% [11] and was recently approved for
weight management in many countries. Exposure to
higher doses was not linked with deterioration in safety
when compared with lower doses but to potential higher
frequency of gastrointestinal side effects [12].
Metformin is an established treatment in PCOS. Despite
being weight neutral as monotherapy, it has multiple
favourable effects mediated through reduction of insulin
resistance and via direct action on steroidogenesis. It
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improves clinical, metabolic and reproductive outcomes of
the syndrome [13–17]. In addition, metformin has a less
defined and less studied potential to enhance the thera-
peutic index of GLP-1 [18–22]. We hypothesized that
metformin may enhance weight-lowering capacity of low
dose liraglutide and provide certain advantages in man-
agement of PCOS related obesity compared to high dose
liraglutide alone.
The purpose of this pilot randomized study was to
compare the combination of metformin and low dose
liraglutide 1.2 mg to high dose liraglutide 3 mg alone on
measures of obesity in obese PCOS.
Methods
Study design
The present study used a 12-week pilot prospective ran-
domized open-label design recruiting 30 obese women
with PCOS. It was conducted at the outpatients Depart-
ment for Endocrinology, Diabetes and Metabolic Dis-
eases University Medical Center Ljubljana. The study
was registered according to the Slovenian drug Law
and retrospectively registered with ClinicalTrials.gov
(NCT02909933) on 16th of September 2016.
The patient inclusion criteria were as follows: type A
phenotype of PCOS diagnosed by ASRM-ESHRE Rotter-
dam criteria including concomitant presence of a) hyper-
androgenemia on either the biochemical or the clinical
level, b) menses abnormalities and c) PCO morphology;
age 18 years to menopause and obesity (body mass
index: BMI ≥ 30). Patients with history of carcinoma, sig-
nificant cardiovascular, kidney or hepatic disease and the
use of medications known to affect reproductive or
metabolic functions within prior to study entry were
excluded.
They were randomized to COMBO or LIRA3 arm. In
COMBO arm, metformin was initiated at a dose of
500 mg once per day and increased up to 1000 mg BID.
Liraglutide was initiated at a dose of 0.6 mg injected s.c.
once per day and increased to 1.2 mg. In LIRA3 arm, lir-
aglutide was initiated at a dose of 0.6 mg injected s.c.
once per day with increments to 3 mg. The primary out-
come of the study was mean change in measures of
obesity. Secondary outcomes included metabolic and
hormonal changes.
At baseline and end of the study all patients under-
went standard anthropometric measurements: height,
weight and waist circumference. BMI was calculated as
the weight in kilograms divided by square of height in
meters. Patients were provided with glucose-monitoring
devices and supplies and educated on their use. They
were instructed to measure blood glucose levels at any
signs and symptoms suggesting low blood glucose.
Hypoglycemia was defined according to American Dia-
betes Association criteria as symptoms suggestive of low
blood glucose confirmed by self-monitored blood glu-
cose measurement below 3.9 mmol/l [23]. All women
were instructed to report any side effects during the
treatment. They were given an advice on recommended
lifestyle intervention that was actively promoted at the
beginning of the study.
A fasting blood was drawn for determination of glu-
cose, insulin, androstenedione, total and free testoster-
one (T) followed by a standard 75 g oral glucose
tolerance test (OGTT) to assess glucose homeostasis.
Glucose levels were determined using a standard glucose
oxidase method (Beckman Coulter Glucose Analyzer,
Beckman Coulter Inc CA, USA). Insulin was determined
by solid-phase enzyme-labeled chemiluminiscent immu-
nometric assay (Immulite 2000 XPi System, Siemens
Healthcare, United Kingdom). Androstenedione was
measured by specific double antibody RIA using 125 I-
labeled hormones (Diagnostic Systems Laboratories,
Webster, Tx). Total and free testosterone levels were
measured by coated tube RIA (DiaSorin, S. p. A, Sallug-
gia, Italy and Diagnostic Products Corporation, LA, re-
spectively). Sex hormone binding globulin (SHBG) was
determined with a chemiluminescent immunoassay
(Immulite 2000 Analyzer, Siemens Healthcare, Erlangen,
Germany). Lipids were determined using Adiva 1800,
Siemens analyzer. Intra-assay variations ranged from 1.6
to 6.3%, and inter-assay variations ranged from 5.8 to
9.6% for the applied methods. Pre- and post-treatment
samples from each patient were assayed in the same
assay run. Homeostasis model assessment (HOMA-IR)
calculation was applied as a measure for insulin resist-
ance (IR). Safety clinical assessment was performed at
the beginning and week 4, 8 and 12 of the treatment
period. Pregnancy was excluded before randomization
by measuring β-human chorionic gonadotropin. Women
were advised to strictly use barrier contraception. They
were informed that there is a very limited knowledge
based on some case reports regarding human exposure
to liraglutide during pregnancy in women with dia-
betes [24].
Statistical analysis
Sample size was determined based on mean change in
weight and data from previous studies with comparative
treatment intervention using Power and Sample Size
Calculation version 3.0.43 [25]. To detect a statistically
significant difference between groups of approximately
2.5 kg in weight loss with 80% power, each group had to
consist of 14 patients. Mean values and standard devi-
ation were used to describe continuous variables. Non-
parametric Wilcoxon signed-rank test for related
samples was used to compare pretreatment and post-
treatment values of continuous variables in each of the
treatment groups. To compare the pretreatment values
Jensterle et al. BMC Endocrine Disorders  (2017) 17:5 Page 2 of 6
and the change of clinical parameters among different
treatment groups, nonparametric Mann–Whitney test
was used. Logistic regression was used to compare the
proportion of patients losing at least 5% of weight. P
values of <0.05 were considered statistically significant.
All statistical analyses were performed using IBM SPSS




The study enrolled 30 participants (aged 33.1 ± 6.1 years,
BMI 38.3 ± 5.4 kg/m2, mean ± SD). Two patients discon-
tinued the study because of protocol violation. Twenty-
eight patients completed the study: 14 on COMBO and
14 on LIRA3. Baseline characteristics of the patients are
provided in Table 1. There were no statistically signifi-
cant differences between both groups (Table 1).
Measures of obesity
The mean post-treatment measures of obesity are pre-
sented in Table 1. At the end of the study, weight and
BMI were significantly decreased in both groups (all p-
values <0.01). Subjects treated with COMBO lost on
average 3.6 ± 2.5 kg compared with a 6.3 ± 3.7 kg weight
loss in LIRA3 group (p = 0.062, Table 2). BMI decreased
for 1.3 ± 0.9 kg/m2 in COMBO arm compared to 2.2 ±
1.3 kg/m2 in LIRA arm with the statistically significant
between treatment differences in BMI (p = 0.05). LIRA3
intervention also resulted in a significant reduction of
waist circumference. The between treatment difference
in the decrease of waist circumference was statistically
significant (Table 2). Clinically meaningful ≥5% weight
reduction was achieved in 35.7% of patients in COMBO
and 57.1% of patients in LIRA3 arm (OR = 0.42, 95% CI
=0.09–1.91), however the between treatment difference
was not statistically significant.
Metabolic parameters
Significant decreases of glucose at 0 and 120 min, insulin
at 0 min of OGTT, HOMA-IR and LDL cholesterol were
observed in the COMBO arm (p = 0.015, p = 0.016, p =
0,035, p = 0.013 and p = 0.049 respectively, Table 1).
LIRA3 resulted in significant improvement of glucose
and insulin levels at 120 min of OGTT (p = 0.002 and p
= 0,008 respectively, Table 1). The between treatment
difference in the parameters of glucose homoeostasis
were not statistically significant, whereas COMBO was
superior in the decrease of LDL cholesterol (Table 2).
Endocrine parameters
Significant decrease of total testosterone was observed in
COMBO arm (p = 0.023), whereas the decrease in LIRA3
was not statistically significant yet. Androstendione and
Table 1 Pretreatment and posttreatment values of clinical parameters of the patients for each treatment group
LIRA3 N = 14 LIRA1.2 + MET2000 N = 14 Comparison of pretreatment
values between groups
Characteristic Pretreatment Post treatment Pa Pretreatment Post treatment Pa Pb
Age (years) 34.6 ± 6.1 31.6 ± 5.9 0.164
Weight (kg) 111.1 ± 14.8 104.7 ± 14.8 0.001 102.5 ± 9 98.9 ± 10.3 0.002 0.137
BMI (kg/m2) 39.2 ± 5.5 37.0 ± 5.5 0.001 37.5 ± 5.3 36.2 ± 5.5 0.002 0.482
Waist circumference (cm) 110.1 ± 12 105.9 ± 12.8 0.003 105.2 ± 10.7 103.0 ± 8.2 0.113 0.265
Androstenedione (nmol/l) 7.0 ± 3.7 7.7 ± 3.4 0.451 10.6 ± 6.4 8.6 ± 3.5 0.530 0.094
Total testosterone (nmol/l) 1.3 ± 0.7 1.2 ± 0.5 0.065 1.8 ± 0.9 1.5 ± 0.8 0.023 0.125
Free testosterone (pmol/l) 9.1 ± 5.1 9.7 ± 3.8 0.594 11.7 ± 5.7 11.0 ± 4.2 0.660 0.164
SHBG (nmol/l) 39.6 ± 41.4 46.9 ± 54.5 0.018 27.7 ± 21.1 47.2 ± 90.4 0.430 0.137
Glu 0 min OGTT (mmol/l) 5.2 ± 0.4 5.1 ± 0.4 0.341 5.4 ± 0.6 5.0 ± 0.3 0.015 0.635
Glu 120 min OGTT (mmol/l) 5.9 ± 1.0 4.7 ± 0.7 0.002 7.1 ± 2.0 5.9 ± 1.6 0.016 0.178
Insulin 0 min OGTT (mU/l) 22 ± 11.7 19.4 ± 10.4 0.272 24.5 ± 18.4 16.8 ± 13.2 0.035 0.839
Insulin 120 min OGTT (mU/l) 86.4 ± 40.3 [2] 68.9 ± 58.4 0.008 118.8 ± 87.5 109.1 ± 127.0 0.551 0.631
HOMA IR 5.1 ± 2.9 4.4 ± 2.4 0.272 5.9 ± 4.3 3.7 ± 3.0 0.013 0.910
Cholesterol (mmol/l) 4.8 ± 0.8 4.8 ± 0.8 0.875 4.9 ± 1.1 [1] 4.5 ± 1.0 [1] 0.107 0.720
HDL cholesterol (mmol/l) 1.3 ± 0.3 1.2 ± 0.3 0.194 1.3 ± 0.1 [1] 1.3 ± 0.2 [1] 0.627 0.239
LDL cholesterol (mmol/l) 2.9 ± 0.8 3.0 ± 0.7 0.928 3.0 ± 0.9 [1] 2.7 ± 0.9 [1] 0.049 0.905
TG (mmol/l) 1.5 ± 0.7 1.6 ± 0.6 0.727 1.4 ± 0.7 [1] 1.2 ± 0.5 [1] 0.075 0.550
data are expressed as mean ± SD
acompared with Wilcoxon signed-rank test for related samples, bold values indicate statistically significant differences
bcompared with nonparametric Mann–Whitney test
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free testosterone decreases tended to be greater in
COMBO compared to LIRA3. In LIRA3 significant in-
crease of SHBG (p = 0.018) was observed (Table 1). There
were no significant between treatment differences in
endocrine parameters (Table 2).
The most common side effects in LIRA3 were nausea
(8/14) and diarrhea (5/14). Vomiting occurred in 1/14
patients and 2/14 mild headache were documented.
Most of the side effects were present in the first 4 weeks
of the treatment, from the 4th to 8th week 2 women had
persistent mild nausea. Adverse effects reported in
COMBO were nausea (6/14), mild diarrhea (6/14), and
insomnia (1/14). All adverse events resolved within the
first 1 to 4 weeks. Hypoglycemic event was reported
once in 1 woman in LIRA3. No side effect was docu-
mented by 6/14 in LIRA3 arm and 8/14 in COMBO
arm. No subject withdrew because of the adverse events
in either group. One woman from LIRA3 had gallblad-
der related symptoms one week after the end of the
study.
Discussion and conclusions
Short-term treatment with high dose liraglutide 3 mg
monotherapy or liraglutide 1.2 mg in adjunct to metfor-
min both resulted in significant within treatment weight
and BMI decrease in obese PCOS. Liraglutide 3 mg was
linked to greater weight reduction and higher proportion
of good responders that lost at least 5% of baseline
weight within 12 weeks. In addition, liraglutide 3 mg led
to significant reduction in waist circumference. However,
a dual-targeting combination treatment with low dose
liraglutide 1.2 mg and metformin resulted in improved
androgen profile that was not observed with LIRA3.
Both regimens improved parameters of glucose homeo-
stasis. In addition, COMBO led to significant within
treatment LDL decrease. Liraglutide 1.2 mg in adjunct
to metformin and liraglutide 3 mg as a monotherapy
were both generally well tolerated with nausea being
more frequent yet transient with liraglutide 3 mg.
Clearly, obesity and obesity related abnormalities are
multifactorial diseases. Treatment algorithms for weight
management should therefore be tailored to specific
obesity related population. In obese PCOS the treatment
should focus on modifiable weight related and weight
nonrelated derangements. The combination treatment
could potentially improve treatment outcomes in obese
PCOS via co-targeting multifactorial origin of obesity
and concomitant abnormalities intrinsically related to
PCOS. Furthermore, the right composition of combin-
ation treatment could enhance the therapeutic index of
the drugs in combination.
Metformin as an add-on to low dose liraglutide seems
to be mechanistically well-suited combination when
obesity is related to PCOS. Metformin alone has well
known beneficial metabolic and gynecological effects in
this population that are mediated through improvement
of IR and via direct action at the ovarian level beyond
weight reduction [13]. Similarly, adding metformin to
liraglutide could potentially enhance GLP-1 effect of lir-
aglutide enabling the use of lower dose of liraglutide in
Table 2 Comparison of absolute change in clinical parameters of PCOS patients among different treatment groups
LIRA3 LIRA1.2 + MET2000 Pa
Characteristic Absolute change mean ± SD Absolute change mean ± SD
Weight (kg) −6.3 ± 3.7 −3.6 ± 2.5 0.062
BMI (kg/m2) −2.2 ± 1.3 −1.3 ± 0.9 0.050
Waist circumference (cm) −4.2 ± 3.4 −2.2 ± 6.2 0.014
Androstenedione (nmol/l) 0.6 ± 2.7 −2.0 ± 6.0 0.376
Total testosterone (nmol/l) −0.2 ± 0.3 −0.3 ± 0.6 0.285
Free testosterone (pmol/l) 0.6 ± 3.3 −0.7 ± 5.3 0.482
SHBG (nmol/l) 7.3 ± 14.2 19.5 ± 71.4 0.376
Glu 0 min OGTT (mmol/l) −0.1 ± 0.4 −0.4 ± 0.6 0.734
Glu 120 min OGTT (mmol/l) −1.2 ± 0.8 −1.1 ± 1.4 0.804
Insulin 0 min OGTT (mU/l) −2.5 ± 9.3 −7.7 ± 16.3 0.571
Insulin 120 min OGTT (mU/l) −30.9 ± 29.5 [2] −9.7 ± 73.4 0.560
HOMA IR −0.7 ± 2.3 −2.1 ± 3.9 0.427
Cholesterol (mmol/l) 0.0 ± 0.4 −0.3 ± 0.6 [1] 0.094
HDL cholesterol (mmol/l) 0.0 ± 0.1 0.0 ± 0.1 [1] 0.793
LDL cholesterol (mmol/l) 0.0. ± 0.3 −0.3 ± 0.4 [1] 0.038
TG (mmol/l) 0.1 ± 0.4 −0.2 ± 0.4 [1] 0.128
acompared with nonparametric Mann–Whitney test, bold values indicate statistically significant differences
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combination treatment. It was demonstrating in animal
studies that metformin increased GLP-1 [22]. In humans
a single dose of metformin also increases GLP-1 after
oral glucose load in non-diabetic subjects [21]. In
addition, chronic exposure to metformin increased GLP-
1 in diabetic and non-diabetic participants [21]. The im-
pact of metformin on weight reducing potential of lira-
glutide could be further explained also through the
stimulation of the expression of GLP-1 receptor and in-
sulin induced signalling pathways [19].
We have previously demonstrated that low dose liraglu-
tide 1.2 mg in combination with metformin in obese pa-
tients with PCOS who had lost less than 5% of body
weight with metformin and lifestyle intervention had bene-
ficial effects compared to low dose liraglutide and metfor-
min monotherapies. After randomization the participants
either continued with metformin or were switched to lira-
glutide 1.2 mg alone or assigned liraglutide 1.2 mg in com-
bination with metformin for 12 weeks. Combination led to
6.5 kg loss compared with 3.8 loss in low dose liraglutide
arm and 1.2 kg in metformin arm [26]. Furthermore, we
observed that metformin added to low dose liraglutide
1.2 mg was more effective than liraglutide 1.2 mg alone in
reducing weight after 12 weeks in treatment naïve obese
PCOS. Addition of metformin resulting in higher propor-
tion of subjects achieving clinically meaningful ≥ 5%
weight reduction in almost 60% compared to about 40% of
good responders in low dose liraglutide monotherapy arm
[27]. Both study designs were conducted with low dose lir-
aglutide 1.2 mg before high dose liraglutide 3 mg was
established as an anti-obesity treatment.
The present study further supports liraglutide 3 mg for
weight reduction in obese PCOS. In 12 weeks almost 60%
of women exposed to liraglutide 3 mg achieved clinically
meaningful ≥ 5% weight loss, that might already improved
cardiovascular risk profile in obese patients [28]. In
addition, high dose liraglutide led to a significant within
treatment reduction of waist circumference, another well-
known independent risk factor for cardiovascular disease.
In line with our observation, dual-energy x-ray absorbtio-
metry of obese patients who were exposed to liraglutide
3 mg for 20 weeks demonstrated that weight reduction
was primarily from decreased fat, including visceral fat, ra-
ther than lean tissue [29]. However, a significant weight
reduction in LIRA 3 group was not yet associated with im-
provement of androgen profile.
The combination treatment of liraglutide 1.2 mg and
metformin also resulted in significant within treatment
reduction of weight in obese PCOS, although the
amount of weight and waist circumference reductions
and the proportion of good responders that lost ≥ 5%
baseline weight were less than in LIRA3 arm. However,
a dual-targeting treatment approach was superior in im-
proving the androgen profile. The observed superior
endocrine effect with COMBO despite the inferior trend
in weight reduction could imply well-known weight in-
dependent action of metformin mediated through direct
regulation of ovarian steroidogenesis [13].
The beneficial effects on glucose metabolism were
comparable in both treatment arms, whereas the LDL
decrease in our study was greater on COMBO compared
to LIRA3. Previous studies with liraglutide have shown
no consistent changes in lipids in subjects with type 2
diabetes [9]. Due to small sample size, general methodo-
logical difficulties in androgen measurements we cannot
provide any firm conclusion about observations regard-
ing endocrine and metabolic parameters that were pre-
specified as secondary outcomes.
High dose liraglutide was not related to deterioration
in general tolerability except higher frequency of dose
dependent nausea. It was present in almost 60% of
women treated with liraglutide 3 mg compared to less
than half of women receiving COMBO. However, all side
effects were transient and mild to moderate, declining
within 4–6 weeks. The adverse events were in line with
the documentation of dose depending adverse events in
phase 2 trial with liraglutide from 1.2 mg up to 3.0 mg,
where 3.0 mg dose induced nausea in almost 50% of par-
ticipants without type 2 diabetes [30]. In phase 3 trials
nausea was induced with lower doses 1.2 and 1.8 mg in
up to 40% of diabetic individuals [31].
The results of our study are subject to several limita-
tions. The duration was too short to assess the sustain-
ability of the benefits from the combination regimen.
Our sample size was small. Future larger designs of lon-
ger duration including the proposed combination treat-
ment in PCOS related obesity could possibly be powered
using our preliminary results. The main strength of this
study was pathophysiological supported strategy com-
bining two medications that act through synergistic
modulation of incretin axis and via direct and indirect
manipulation of intrinsic weight independent abnormal-
ities in this specific obesity related population.
Overall, the selection of the right combination for the
combination treatment is a complex task that requires
understanding of pathophysiological backgrounds of the
obesity and obesity related comorbidities. The results of
this study indicated the potential benefits of combin-
ation of low dose liraglutide and metformin in the man-
agement of obese PCOS. Our results are preliminary,
but support future investigations of this dual treatment
approach when obesity is linked to PCOS.
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